Current therapies for eosinophilic disorders are limited. Most treatment approaches remain empirical, are not supported by data from controlled clinical trials, involve the off-label use of agents developed for treatment of other diseases, and tend to rely heavily on the use of glucocorticoids and other agents with significant toxicity. Great progress has been made in the discovery, preclinical development, and clinical testing of a variety of biologics and small molecules that have the potential to directly or indirectly influence eosinophils, eosinophilic inflammation, and the consequences of eosinophil activation.
|Original language||English (US)|
|Number of pages||22|
|Journal||Immunology and Allergy Clinics of North America|
|State||Published - Aug 1 2015|
ASJC Scopus subject areas
- Immunology and Allergy